vs
Side-by-side financial comparison of ASTRONICS CORP (ATRO) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
ASTRONICS CORP is the larger business by last-quarter revenue ($240.1M vs $129.7M, roughly 1.9× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 15.1%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 13.9%).
Astronics Corporation is an American aerospace electronics corporation founded in 1968, headquartered in East Aurora, New York. It is traded on NASDAQ as Nasdaq: ATRO. It is known for lighting and electronics integrations on military, commercial, and business aircraft and semiconductor test systems.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
ATRO vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $240.1M | $129.7M |
| Net Profit | — | — |
| Gross Margin | 33.3% | 98.0% |
| Operating Margin | 14.8% | -25.0% |
| Net Margin | — | — |
| Revenue YoY | 15.1% | 73.4% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.82 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $240.1M | $129.7M | ||
| Q3 25 | $211.4M | $164.9M | ||
| Q2 25 | $204.7M | $114.4M | ||
| Q1 25 | $205.9M | $81.7M | ||
| Q4 24 | $208.5M | $74.8M | ||
| Q3 24 | $203.7M | $62.9M | ||
| Q2 24 | $198.1M | $54.1M | ||
| Q1 24 | $185.1M | $41.4M |
| Q4 25 | — | — | ||
| Q3 25 | $-11.1M | $25.7M | ||
| Q2 25 | $1.3M | $-12.8M | ||
| Q1 25 | $9.5M | $-41.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-11.7M | $-54.8M | ||
| Q2 24 | $1.5M | $-70.4M | ||
| Q1 24 | $-3.2M | $-136.1M |
| Q4 25 | 33.3% | 98.0% | ||
| Q3 25 | 30.5% | 99.0% | ||
| Q2 25 | 25.8% | 98.7% | ||
| Q1 25 | 29.5% | 94.3% | ||
| Q4 24 | 29.8% | 96.6% | ||
| Q3 24 | 27.1% | 97.4% | ||
| Q2 24 | 28.0% | 96.2% | ||
| Q1 24 | 25.7% | 96.4% |
| Q4 25 | 14.8% | -25.0% | ||
| Q3 25 | 10.9% | 15.1% | ||
| Q2 25 | 2.3% | -11.1% | ||
| Q1 25 | 6.4% | -52.2% | ||
| Q4 24 | 4.3% | -81.2% | ||
| Q3 24 | 4.1% | -89.3% | ||
| Q2 24 | 3.8% | -125.1% | ||
| Q1 24 | 0.9% | -336.5% |
| Q4 25 | — | — | ||
| Q3 25 | -5.2% | 15.6% | ||
| Q2 25 | 0.6% | -11.1% | ||
| Q1 25 | 4.6% | -50.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | -5.8% | -87.1% | ||
| Q2 24 | 0.8% | -130.1% | ||
| Q1 24 | -1.7% | -328.9% |
| Q4 25 | $0.82 | $0.04 | ||
| Q3 25 | $-0.31 | $0.28 | ||
| Q2 25 | $0.04 | $-0.14 | ||
| Q1 25 | $0.26 | $-0.47 | ||
| Q4 24 | $-0.07 | $-0.71 | ||
| Q3 24 | $-0.34 | $-0.70 | ||
| Q2 24 | $0.04 | $-0.91 | ||
| Q1 24 | $-0.09 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.2M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $140.1M | $114.8M |
| Total Assets | $706.7M | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | $93.0M | ||
| Q3 25 | $13.5M | $110.9M | ||
| Q2 25 | $13.5M | $75.2M | ||
| Q1 25 | $24.8M | $61.9M | ||
| Q4 24 | $9.3M | $58.5M | ||
| Q3 24 | $5.2M | $36.4M | ||
| Q2 24 | $2.9M | $32.3M | ||
| Q1 24 | $5.3M | $43.3M |
| Q4 25 | $140.1M | $114.8M | ||
| Q3 25 | $108.9M | $73.6M | ||
| Q2 25 | $271.6M | $32.7M | ||
| Q1 25 | $266.8M | $32.8M | ||
| Q4 24 | $256.1M | $59.1M | ||
| Q3 24 | $249.2M | $-30.5M | ||
| Q2 24 | $257.9M | $15.1M | ||
| Q1 24 | $251.7M | $74.1M |
| Q4 25 | $706.7M | $605.2M | ||
| Q3 25 | $682.2M | $538.6M | ||
| Q2 25 | $646.7M | $555.3M | ||
| Q1 25 | $662.2M | $548.8M | ||
| Q4 24 | $648.8M | $594.1M | ||
| Q3 24 | $651.6M | $504.4M | ||
| Q2 24 | $644.9M | $551.1M | ||
| Q1 24 | $630.0M | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $27.6M | $60.7M |
| Free Cash FlowOCF − Capex | $15.8M | — |
| FCF MarginFCF / Revenue | 6.6% | — |
| Capex IntensityCapex / Revenue | 4.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.6M | $60.7M | ||
| Q3 25 | $34.2M | $14.3M | ||
| Q2 25 | $-7.6M | $5.0M | ||
| Q1 25 | $20.6M | $-42.2M | ||
| Q4 24 | $26.4M | $-35.7M | ||
| Q3 24 | $8.4M | $-42.5M | ||
| Q2 24 | $-6.3M | $-40.2M | ||
| Q1 24 | $2.0M | $-119.0M |
| Q4 25 | $15.8M | — | ||
| Q3 25 | $21.0M | $14.2M | ||
| Q2 25 | $-12.2M | — | ||
| Q1 25 | $18.5M | — | ||
| Q4 24 | $23.2M | — | ||
| Q3 24 | $6.5M | — | ||
| Q2 24 | $-8.1M | $-40.3M | ||
| Q1 24 | $439.0K | — |
| Q4 25 | 6.6% | — | ||
| Q3 25 | 9.9% | 8.6% | ||
| Q2 25 | -6.0% | — | ||
| Q1 25 | 9.0% | — | ||
| Q4 24 | 11.1% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | -4.1% | -74.5% | ||
| Q1 24 | 0.2% | — |
| Q4 25 | 4.9% | — | ||
| Q3 25 | 6.2% | 0.1% | ||
| Q2 25 | 2.2% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 0.9% | 0.0% | ||
| Q2 24 | 0.9% | 0.2% | ||
| Q1 24 | 0.9% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | -5.81× | — | ||
| Q1 25 | 2.17× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.08× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATRO
| Product Line Electrical Power And Motion | $113.8M | 47% |
| Product Line Avionics | $32.0M | 13% |
| Military Aircraft | $28.0M | 12% |
| General Aviation | $22.3M | 9% |
| Government And Defense | $20.5M | 9% |
| Product Line Systems Certification | $13.2M | 6% |
| Product Line Structures | $3.7M | 2% |
| Product Line Other | $2.3M | 1% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
